DRG 3.0 Reshapes Hospital Economics; CMDE Opens 16 Class II IVD Guidelines for Comment
China's medical device sector this week faces converging pressures: DRG 3.0's finer grouping and robotic-surgery codes force device makers to prove value per case, while CMDE's 16 new Class II IVD guidelines and the full UDI rollout raise the compliance bar for registration and traceability.
01CMDE Releases 16 Draft Class II IVD Registration Guidelines
On September 1, 2026, China's Center for Medical Device Evaluation (CMDE) issued 16 draft registration and review guidelines for Class II in vitro diagnostic (IVD) reagents and devices, opening public comment through October 8, 2026. The lead document covers parathyroid hormone assay reagents, with the full batch spanning immunoassay kits, clinical chemistry reagents, and molecular diagnostics. The consolidated guidance reduces interpretive ambiguity for Class II IVD manufacturers and is expected to be finalized in early 2027, establishing the regulatory baseline for the remainder of the decade. The bulk release signals CMDE's shift toward systematic catalog-wide standardization rather than reactive product-specific rulemaking.
02DRG 3.0 Launches: 825 Groups and 9 Robotic-Surgery Codes Rewrite Device Economics
On September 2, 2026, the National Healthcare Security Administration officially released Diagnosis-Related Groups (DRG) version 3.0, expanding core groups from 409 to 492 and fine groups from 634 to 825. For the first time at the national level, 158 primary-level disease categories and 9 robotic-assisted surgery sub-groups were explicitly defined. Under DRG, hospital reimbursement is decoupled from actual cost: an innovative device that adds RMB 8,000 to a case can push the hospital into deficit even if the technology is clinically superior. Device companies must now articulate not just product price and reimbursement code, but how the product changes the case's total resource consumption. The 3.0 update signals the payment system's willingness to recognize innovation that alters cost structures, provided sufficient clinical scale and data accumulation.
03UDI Rollout Expands to All Class II by 2027 and All Class I by 2029
The NMPA, National Health Commission, and National Healthcare Security Administration jointly issued Announcement No. 21 (2026), extending the Unique Device Identification (UDI) mandate beyond the existing Class III and 103 Class II products. All Class II devices (including IVD reagents) produced from June 1, 2027 must carry UDI, with all Class I devices following by June 1, 2029. Distributors are required to scan codes in and out of inventory and upload data to the national medical insurance platform, while hospitals must apply UDI across clinical use, adverse event reporting, payment, and settlement. The schedule compresses compliance timelines for smaller manufacturers and reinforces traceability from production through clinical use, further tightening distribution channel requirements.
04Online Sales Rules Tighten as Distribution Giants Embrace O2O
NMPA's revised draft Measures for the Supervision and Administration of Medical Device Online Sales (comment period closed August 26, 2026) strengthens platform responsibilities: e-commerce platforms must verify seller qualifications every six months, display registration and license information prominently, retain transaction and logistics records for at least five years, and set up 24-hour complaint channels. Parallel to regulation, Jiuzhoutong signed a three-year strategic agreement with JD Health targeting over RMB 10 billion in cooperation scale, focusing on supply-chain data sharing, multi-warehouse inventory management, and O2O instant retail via JD's "miaosong" network for minute-level delivery. The convergence of stricter platform accountability and giant distributor-ecommerce alliances signals a channel shift toward compliant, data-driven, and instant-fulfillment medical device retail.
Want to know how these changes affect your product?
Our regulatory team offers a free assessment with concrete impact analysis within 5 business days.
Free Consultation